Duquesne Family Office LLC Takes $4.23 Million Position in IQVIA Holdings Inc. (NYSE:IQV)

Duquesne Family Office LLC bought a new position in shares of IQVIA Holdings Inc. (NYSE:IQV) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 21,500 shares of the medical research company’s stock, valued at approximately $4,225,000.

A number of other institutional investors have also modified their holdings of the business. Synergy Asset Management LLC purchased a new position in IQVIA during the 4th quarter worth $33,000. GKV Capital Management Co. Inc. acquired a new stake in shares of IQVIA during the fourth quarter worth about $39,000. Lee Danner & Bass Inc. purchased a new position in shares of IQVIA during the fourth quarter worth about $44,000. Zions Bancorporation N.A. increased its position in IQVIA by 55.2% in the 4th quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company’s stock valued at $47,000 after acquiring an additional 85 shares during the period. Finally, SBI Securities Co. Ltd. purchased a new stake in IQVIA during the 4th quarter valued at approximately $60,000. 89.62% of the stock is owned by institutional investors and hedge funds.

IQVIA Trading Down 4.1 %

Shares of IQVIA stock opened at $146.12 on Wednesday. The business has a 50 day moving average price of $165.94 and a 200 day moving average price of $189.86. The company has a market capitalization of $25.76 billion, a P/E ratio of 19.48, a P/E/G ratio of 1.99 and a beta of 1.34. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. IQVIA Holdings Inc. has a 1 year low of $135.97 and a 1 year high of $252.88.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Sell-side analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the company. Morgan Stanley boosted their target price on IQVIA from $245.00 to $250.00 and gave the company an “overweight” rating in a report on Tuesday, February 11th. JPMorgan Chase & Co. cut their price objective on shares of IQVIA from $240.00 to $232.00 and set an “overweight” rating for the company in a research report on Tuesday, February 18th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $270.00 target price on shares of IQVIA in a report on Monday, February 10th. Citigroup cut their price target on shares of IQVIA from $225.00 to $210.00 and set a “neutral” rating for the company in a report on Tuesday, March 4th. Finally, Truist Financial lowered their price objective on IQVIA from $263.00 to $216.00 and set a “buy” rating on the stock in a report on Thursday, April 10th. Eight investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $237.62.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.